
|Articles|June 3, 2015
Bringing a Biologic from the Bench to the Marketplace
Author(s)Randi Hernandez
Michiel E. Ultee of Ulteemit BioConsulting discusses converting an early drug discovery into a product that is ready for clinical testing.
Advertisement
In this video, Michiel E. Ultee, PhD, principal of Ulteemit BioConsulting, discusses converting an early drug discovery into a product that is ready for clinical testing, biologics license applications, and FDA guidance documents.
The video was shot at INTERPHEX 2015 in New York, NY.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Fast Tracks Innovent’s Trispecific Antibody for Multiple Myeloma
2
FDA Priority Review of Subcutaneous Lecanemab Signals Shift in Alzheimer’s Treatment Delivery
3
HanchorBio–WuXi Biologics Partnership Targets Fusion Protein Development Challenges
4
GSK’s Arexvy Gains EU Approval for Adults Aged 18 Years and Older
5




